HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NI-0101

an anti-TLR4 antibody; in phase I clinical trials (2017)

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Choy, Ernest H: 1 article (01/2020)
2.	Jacqmin, Philippe: 1 article (01/2020)
3.	Kobakhidze, Tamta: 1 article (01/2020)
4.	Lapeyre, Geneviève: 1 article (01/2020)
5.	McInnes, Iain: 1 article (01/2020)
6.	Monnet, Emmanuel: 1 article (01/2020)
7.	de Graaf, Kathy: 1 article (01/2020)
8.	de Min, Cristina: 1 article (01/2020)
9.	Hodgkinson, Lisa: 1 article (07/2010)

Related Diseases

1.	Reperfusion Injury 07/01/2010 - "This conference report highlights selected presentations on the apolipoprotein E-mimetic peptide COG-112 (Cognosci Inc) for the potential treatment of Citrobacter rodentium-induced colitis; the inhibition of sphingosine kinase with ABC-294640 (Apogee Biotechnology Corp) to alleviate stress after hepatic ischemia-reperfusion injury; TLR4 targeting with NI-0101 (NovImmune SA) to prevent colitis-associated cancer; immunization against TNF with TNFalpha kinoid (Neovacs SA) for the treatment of patients with Crohn's disease; and preclinical studies with the anti-inflammatory agent minnelide (University of Minnesota) for the treatment of pancreatic cancer."
2.	Pancreatic Neoplasms (Pancreatic Cancer) 07/01/2010 - "This conference report highlights selected presentations on the apolipoprotein E-mimetic peptide COG-112 (Cognosci Inc) for the potential treatment of Citrobacter rodentium-induced colitis; the inhibition of sphingosine kinase with ABC-294640 (Apogee Biotechnology Corp) to alleviate stress after hepatic ischemia-reperfusion injury; TLR4 targeting with NI-0101 (NovImmune SA) to prevent colitis-associated cancer; immunization against TNF with TNFalpha kinoid (Neovacs SA) for the treatment of patients with Crohn's disease; and preclinical studies with the anti-inflammatory agent minnelide (University of Minnesota) for the treatment of pancreatic cancer."
3.	Crohn Disease (Crohn's Disease) 07/01/2010 - "This conference report highlights selected presentations on the apolipoprotein E-mimetic peptide COG-112 (Cognosci Inc) for the potential treatment of Citrobacter rodentium-induced colitis; the inhibition of sphingosine kinase with ABC-294640 (Apogee Biotechnology Corp) to alleviate stress after hepatic ischemia-reperfusion injury; TLR4 targeting with NI-0101 (NovImmune SA) to prevent colitis-associated cancer; immunization against TNF with TNFalpha kinoid (Neovacs SA) for the treatment of patients with Crohn's disease; and preclinical studies with the anti-inflammatory agent minnelide (University of Minnesota) for the treatment of pancreatic cancer."
4.	Colitis 07/01/2010 - "This conference report highlights selected presentations on the apolipoprotein E-mimetic peptide COG-112 (Cognosci Inc) for the potential treatment of Citrobacter rodentium-induced colitis; the inhibition of sphingosine kinase with ABC-294640 (Apogee Biotechnology Corp) to alleviate stress after hepatic ischemia-reperfusion injury; TLR4 targeting with NI-0101 (NovImmune SA) to prevent colitis-associated cancer; immunization against TNF with TNFalpha kinoid (Neovacs SA) for the treatment of patients with Crohn's disease; and preclinical studies with the anti-inflammatory agent minnelide (University of Minnesota) for the treatment of pancreatic cancer."
5.	Rheumatoid Arthritis 01/01/2020 - "Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study."

Related Drugs and Biologics

1.	Toll-Like Receptor 4
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.	Peptides (Polypeptides)
4.	Methotrexate (Mexate)
5.	Apolipoproteins
6.	Monoclonal Antibodies
7.	Anti-Inflammatory Agents (Anti-Inflammatories)
8.	14-O-phosphonooxymethyltriptolide disodium salt
9.	3- (4- chlorophenyl)- adamantane- 1- carboxylic acid (pyridin-4-ylmethyl)amide
10.	sphingosine kinase